http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 01 Jul 2026 16:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+24/26720478.html si-local-file:///var/storage/secattach/20260701/26720478.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+24/26720478.html Wed, 01 Jul 2026 16:01:00 -0400 O.00180660 SGMO SGMOQ http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+24/26720478.html si-local-file:///var/storage/secattach/20260701/26720478.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+24/26720478.html Wed, 01 Jul 2026 16:01:00 -0400 O.00180660 SGMO SGMOQ http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+24/26720478.html si-local-file:///var/storage/secattach/20260701/26720478.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+24/26720478.html Wed, 01 Jul 2026 16:01:00 -0400 O.00180660 SGMO SGMOQ http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+18/26680154.html si-local-file:///var/storage/secattach/20260623/26680154.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+18/26680154.html Tue, 23 Jun 2026 16:42:00 -0400 O.00180660 SGMO http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+18/26680154.html si-local-file:///var/storage/secattach/20260623/26680154.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+18/26680154.html Tue, 23 Jun 2026 16:42:00 -0400 O.00180660 SGMO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+18/26676611.html si-local-file:///var/storage/secattach/20260623/26676611.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+18/26676611.html Tue, 23 Jun 2026 08:46:00 -0400 O.00180660 SGMO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+18/26676611.html si-local-file:///var/storage/secattach/20260623/26676611.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Jun+18/26676611.html Tue, 23 Jun 2026 08:46:00 -0400 O.00180660 SGMO http://www.streetinsider.com/Corporate+News/Sangamo+files+Chapter+11%2C+agrees+to+sell+assets+to+Lilly%2C+Astellas/26676278.html <p>Sangamo Therapeutics (OTCQB: SGMO) has filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware and entered into two separate asset sale agreements as part of a court-supervised reorganization process.</p><p>Under the agreements, Eli Lilly and Company will serve as a stalking horse bidder for Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform, and the prion disease program ST-506. Astellas Pharma Inc. will serve as stalking horse bidder for Sangamo's Fabry disease program, isaralgagene civaparvovec, also known as ST-920.</p><p>Additional assets not included in either stalking horse bid — including the ST-503 chronic http://www.streetinsider.com/Corporate+News/Sangamo+files+Chapter+11%2C+agrees+to+sell+assets+to+Lilly%2C+Astellas/26676278.html Tue, 23 Jun 2026 08:05:38 -0400 LLY SGMO http://www.streetinsider.com/Corporate+News/Sangamo+files+Chapter+11%2C+agrees+to+sell+assets+to+Lilly%2C+Astellas/26676278.html <p>Sangamo Therapeutics (OTCQB: SGMO) has filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware and entered into two separate asset sale agreements as part of a court-supervised reorganization process.</p><p>Under the agreements, Eli Lilly and Company will serve as a stalking horse bidder for Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform, and the prion disease program ST-506. Astellas Pharma Inc. will serve as stalking horse bidder for Sangamo's Fabry disease program, isaralgagene civaparvovec, also known as ST-920.</p><p>Additional assets not included in either stalking horse bid — including the ST-503 chronic http://www.streetinsider.com/Corporate+News/Sangamo+files+Chapter+11%2C+agrees+to+sell+assets+to+Lilly%2C+Astellas/26676278.html Tue, 23 Jun 2026 08:05:38 -0400 LLY SGMO http://www.streetinsider.com/Mergers+and+Acquisitions/Sangamo+files+Chapter+11%2C+agrees+to+sell+assets+to+Lilly%2C+Astellas/26676278.html <p>Sangamo Therapeutics (OTCQB: SGMO) has filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware and entered into two separate asset sale agreements as part of a court-supervised reorganization process.</p><p>Under the agreements, Eli Lilly and Company will serve as a stalking horse bidder for Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform, and the prion disease program ST-506. Astellas Pharma Inc. will serve as stalking horse bidder for Sangamo's Fabry disease program, isaralgagene civaparvovec, also known as ST-920.</p><p>Additional assets not included in either stalking horse bid — including the ST-503 chronic http://www.streetinsider.com/Mergers+and+Acquisitions/Sangamo+files+Chapter+11%2C+agrees+to+sell+assets+to+Lilly%2C+Astellas/26676278.html Tue, 23 Jun 2026 08:05:38 -0400 LLY SGMO http://www.streetinsider.com/Mergers+and+Acquisitions/Sangamo+files+Chapter+11%2C+agrees+to+sell+assets+to+Lilly%2C+Astellas/26676278.html <p>Sangamo Therapeutics (OTCQB: SGMO) has filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware and entered into two separate asset sale agreements as part of a court-supervised reorganization process.</p><p>Under the agreements, Eli Lilly and Company will serve as a stalking horse bidder for Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform, and the prion disease program ST-506. Astellas Pharma Inc. will serve as stalking horse bidder for Sangamo's Fabry disease program, isaralgagene civaparvovec, also known as ST-920.</p><p>Additional assets not included in either stalking horse bid — including the ST-503 chronic http://www.streetinsider.com/Mergers+and+Acquisitions/Sangamo+files+Chapter+11%2C+agrees+to+sell+assets+to+Lilly%2C+Astellas/26676278.html Tue, 23 Jun 2026 08:05:38 -0400 LLY SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html <p align="center"><em>Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders</em></p> <p align="center"><em>Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process</em></p> <p align="center"><em>Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p align="justify">RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli Lilly and Company (“Lilly”) for Sangamo’s capsid delivery http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Enters+Into+Asset+Sale+Agreements+with+Lilly+and+Astellas/26676264.html Tue, 23 Jun 2026 08:05:00 -0400 A.07414818 A.12981302 A.50204190 O.00046770 O.00180660 O.00980350 O.03227691 SGMO